- Home
- PSNL
PSNL
Personalis Inc.
as 01-17-2025 4:00pm EST
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 460.7M | IPO Year: | 2019 |
| Target Price: | $8.56 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $7.20 | Next Earning Date: | 02-26-2025 |
| Revenue: | $87,489,000 | Revenue Growth: | 24.05% |
| Revenue Growth (this year): | 15.76% | Revenue Growth (next year): | 4.90% |
Stock Insider Trading Activity of Personalis Inc. (PSNL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Dec 16 '24 | Sell | $3.82 | 4,834 | $18,465.88 | 123,886 | |
| Tachibana Aaron | PSNL | CFO AND COO | Dec 16 '24 | Sell | $3.82 | 6,865 | $26,224.30 | 167,098 | |
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | Dec 16 '24 | Sell | $3.82 | 1,513 | $5,779.66 | 65,875 | |
| Chen Richard | PSNL | CHIEF MEDICAL OFFICER AND EVP | Nov 18 '24 | Sell | $3.79 | 921 | $3,490.59 | 123,886 | |
| Tachibana Aaron | PSNL | CFO AND COO | Nov 18 '24 | Sell | $3.79 | 1,307 | $4,953.53 | 167,098 | |
| Moore Stephen Michael | PSNL | SVP and Chief Legal Officer | Nov 18 '24 | Sell | $3.79 | 1,693 | $6,416.47 | 65,875 | |
| Hall Christopher M | PSNL | PRESIDENT AND CEO | Nov 1 '24 | Sell | $5.38 | 26,443 | $142,263.34 | 178,098 |
Latest Personalis Inc. News
PSNL Breaking Stock News: Dive into PSNL Ticker-Specific Updates for Smart Investing
Medical Device Network
6 days ago
Researchers find ctDNA test predicts lung cancer outcomes in study
MT Newswires
6 days ago
Personalis Says Study Shows NeXT Personal Test's 'High Sensitivity' for Lung Cancer Detection
Business Wire
6 days ago
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
MT Newswires
11 days ago
Personalis Reports Lower Preliminary Revenue for Q4
Business Wire
11 days ago
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
Simply Wall St.
24 days ago
The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159%
TipRanks
a month ago
Personalis price target raised to $8 from $7 at BTIG
MT Newswires
a month ago
Personalis Rallies Following $50 Million Investment from Merck, Extended Agreement With Moderna
Compare PSNL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSNL Personalis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.